Agilent Technologies, Inc. (NYSE: A) today introduced the Agilent SureCycler 8800, a full-featured thermal cycler that eliminates the need to choose between popular features of other major PCR instruments.
“Now customers can have a brand new system that combines the best features of leading PCR instruments, and equip their genomic workflows with a single, trusted vendor from start to finish”
The SureCycler 8800 expands Agilent's portfolio of PCR solutions, including a full selection of enzymes, RT-PCR kits and mutagenesis kits.
The Agilent SureCycler 8800 delivers high speed and high volume in the same instrument, so users aren't forced to choose between the two. The modular design accommodates both 96-well and 384-well microtiter plates for additional flexibility. The instrument also features temperature gradient capability without sacrificing market-leading uniformity. The high-quality touchscreen and intuitive software contribute to the SureCycler 8800's productivity and convenience.
"Now customers can have a brand new system that combines the best features of leading PCR instruments, and equip their genomic workflows with a single, trusted vendor from start to finish," said Carolyn Reifsnyder, marketing director, QPCR, PCR & Bioreagents, Agilent Genomics Division. "Along with providing Agilent's line of PCR reagents and kits, we remain committed to driving innovation in life-science research with complete, customer-focused solutions."
In addition to now having one trusted partner for all PCR needs, customers also gain access to Agilent's technical expertise in designing assays and optimizing protocols for their workflows. The SureCycler 8800 also leverages Agilent's Electronic Measurement Group's expertise in precision manufacturing. The instrument joins the company's line of high quality life-science instrumentation, including the Mx3005P QPCR instrument, 2100 BioAnalyzer and SureSelect XT workflow automation system for target enrichment.
The SureCycler 8800 is on display in Agilent's booth (1201) at the American Association for Cancer Research, April 2-6 in Orlando, Fla.
New research explores how antimicrobial exposure affects Parkinson’s disease risk